Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.Rebecca Gardner, Michael C. Jensen, Wenjun Huang et al.|Journal of Clinical Oncology|2020Cited by 13
Apheresis education in Canadian residency programs: A needs assessmentAmanda Li, Christopher J. Patriquin, Katerina Pavenski et al.|Transfusion and Apheresis Science|2020Cited by 4
Durable Clinical Benefits in Transfusion-Dependent Β-Thalassemia with Exagamglogene AutotemcelHaydar Frangoul, William Hobbs, Franco Locatelli et al.|Transplantation and Cellular Therapy|2025Cited by 1